JP2014520786A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520786A5
JP2014520786A5 JP2014517820A JP2014517820A JP2014520786A5 JP 2014520786 A5 JP2014520786 A5 JP 2014520786A5 JP 2014517820 A JP2014517820 A JP 2014517820A JP 2014517820 A JP2014517820 A JP 2014517820A JP 2014520786 A5 JP2014520786 A5 JP 2014520786A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520786A (ja
JP6101260B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063242 external-priority patent/WO2013004816A1/en
Publication of JP2014520786A publication Critical patent/JP2014520786A/ja
Publication of JP2014520786A5 publication Critical patent/JP2014520786A5/ja
Application granted granted Critical
Publication of JP6101260B2 publication Critical patent/JP6101260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517820A 2011-07-07 2012-07-06 ダルナビル製剤 Active JP6101260B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173066.9 2011-07-07
EP11173066 2011-07-07
PCT/EP2012/063242 WO2013004816A1 (en) 2011-07-07 2012-07-06 Darunavir formulations

Publications (3)

Publication Number Publication Date
JP2014520786A JP2014520786A (ja) 2014-08-25
JP2014520786A5 true JP2014520786A5 (enExample) 2015-07-16
JP6101260B2 JP6101260B2 (ja) 2017-03-22

Family

ID=46458539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517820A Active JP6101260B2 (ja) 2011-07-07 2012-07-06 ダルナビル製剤

Country Status (23)

Country Link
US (3) US20140142174A1 (enExample)
EP (1) EP2729128B1 (enExample)
JP (1) JP6101260B2 (enExample)
KR (1) KR101817991B1 (enExample)
CN (1) CN103841962B (enExample)
AU (1) AU2012280277B2 (enExample)
BR (1) BR112014000195A2 (enExample)
CA (1) CA2837539C (enExample)
CY (1) CY1119446T1 (enExample)
DK (1) DK2729128T3 (enExample)
EA (1) EA026588B1 (enExample)
ES (1) ES2598823T3 (enExample)
HR (1) HRP20161340T1 (enExample)
HU (1) HUE030341T2 (enExample)
IL (1) IL229700B (enExample)
LT (1) LT2729128T (enExample)
MX (1) MX341976B (enExample)
PL (1) PL2729128T3 (enExample)
PT (1) PT2729128T (enExample)
RS (1) RS55236B1 (enExample)
SI (1) SI2729128T1 (enExample)
SM (1) SMT201600380B (enExample)
WO (1) WO2013004816A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700574T1 (it) 2011-07-07 2018-01-11 Gilead Sciences Inc Formulazioni delle combinazioni di darunavir
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3210017B1 (en) 2014-10-26 2021-10-06 King Abdullah University Of Science And Technology Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (hiv)
EP4696309A2 (en) 2017-07-20 2026-02-18 Janssen Sciences Ireland Unlimited Company Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス,インコーポレイティド Ag10の製剤
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
US20210290590A1 (en) 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
MX2022013090A (es) * 2020-04-20 2022-11-14 Poviva Corp Composiciones y metodos para el suministro mejorado de agentes antivirales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ES2604662T3 (es) 1998-06-23 2017-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ensayo de acondicionamiento físico y métodos para reducir la resistencia del VIH a la terapia
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
CA2689330A1 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Combination formulations
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8703980B2 (en) * 2009-09-17 2014-04-22 Siva Rama Prasad Vellanki Process for the preparation of darunavir

Similar Documents

Publication Publication Date Title
JP2011093937A5 (enExample)
JP2013539946A5 (enExample)
JP2014503786A5 (enExample)
JP2013531034A5 (enExample)
JP2013531018A5 (enExample)
JP2014026276A5 (enExample)
JP2014026275A5 (enExample)
JP2014026274A5 (enExample)
JP2012204203A5 (enExample)
JP2014505137A5 (enExample)
JP2012031285A5 (enExample)
JP2015500269A5 (enExample)
JP2013064178A5 (enExample)
JP2014189812A5 (enExample)
JP2014520787A5 (enExample)
JP2012193264A5 (enExample)
JP2014520786A5 (enExample)
JP2012190699A5 (enExample)
JP2014531903A5 (enExample)
JP2014534151A5 (enExample)
JP2016505534A5 (enExample)
JP2011233516A5 (enExample)
JP2014205658A5 (enExample)
JP2014005521A5 (enExample)
JP2013016377A5 (enExample)